Kadohira Yasuko, Yamada Shinya, Matsuura Erika, Hayashi Tomoe, Morishita Eriko, Nakao Shinji, Asakura Hidesaku
Department of Hematology, Kanazawa University Hospital, Japan.
Intern Med. 2017 Nov 1;56(21):2913-2917. doi: 10.2169/internalmedicine.8666-16. Epub 2017 Sep 25.
We describe a case in which uncontrolled chronic disseminated intravascular coagulation (DIC) caused by an aortic aneurysm that was exacerbated by chemotherapy for lung cancer, showed dramatic improvement when warfarin, which was being administered for atrial fibrillation, was replaced by rivaroxaban, a direct oral anticoagulant (DOAC). The present case is interesting because a DOAC was effective in treating DIC due to an aortic aneurysm, whereas warfarin, another oral anticoagulant, was ineffective. In controlling DIC, it is important to inhibit activated coagulation factors such as thrombin and activated factor X, rather than the coagulation factors, which act as substrates.
一名患者因主动脉瘤引发了失控的慢性弥散性血管内凝血(DIC),而肺癌化疗使其病情加重,在将用于房颤治疗的华法林换成直接口服抗凝剂(DOAC)利伐沙班后,病情显著改善。本病例很有意思,因为一种DOAC对治疗由主动脉瘤引起的DIC有效,而另一种口服抗凝剂华法林却无效。在控制DIC时,抑制凝血酶和活化的X因子等活化凝血因子而非作为底物的凝血因子很重要。